MH

Michelle Ho

VP Strategy and Operations at Renasant Bio

San Francisco Bay Area

Invests in

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

  • VP Strategy and Operations

    2024

2018 - 2024

  • Operating Principal

    2023 - 2024

  • Senior Associate

    2022 - 2022

  • Associate

    2020 - 2021

  • Analyst

    2018 - 2019

2021 - 2024

  • Board Observer

    2021 - 2024

2021 - 2024

  • Board Observer

    2021 - 2024

2018 - 2024

  • Board Observer

    2018 - 2024

  • Board Observer

    2020 - 2024

  • Board Observer

    2019 - 2023

2022 - 2022

  • Board Observer

    2022 - 2022

    Acquired by Bionano Genomics in November 2022

  • Entrepreneurship Fellow

    2016 - 2018

    • Managed 2 portfolio life science startups in therapeutics (rHDL therapeutics) and medical devices (GuidaBot) • Developed pitch decks and led business development efforts, including key collaboration with leading siRNA biotech company • Performed market analysis, product-market-fit, and business model development for portfolio technologies • Initiated 2 new collaborations with NASH and rare metabolic disease experts • Awarded $325k NIH SBIR Phase I grant for development and safety/toxicity assessment of novel lipid-based nanoparticles for therapeutic siRNA delivery • Created and led monthly entrepreneurship book club • Led branding and outreach efforts for Fannin Innovation Studio

2016 - 2018

  • Director of Operations

    2016 - 2018

    • Led business development, validated value propositions via customer interviews with key opinion leaders in functional neurosurgery and shadowing laser ablation procedures • Directed prototype development of robotic MRI-compatible neurosurgical guidance device • Determined regulatory and go-to-market strategy • Awarded $225k NSF STTR Phase I grant to develop proof-of-concept 4-DoF robotic prototype • Won 1st Place Elevator Pitch at Texas A&M New Ventures Competition 2017 • Won acceptance into TMCx Medical Device Accelerator - Class 5 Cohort